GET DAILY SIGNALSImmunic (IMUX) Shares Could Climb +307% to Hit $31 Analyst Target
Key Takeaways
- The central target used here is $31, the arithmetic mean of seven current, individually verified analyst price targets that identify the analyst, firm, target, and date.
- The verified targets range widely, from $12.19 (Leerink Partners) to $56 (LifeSci Capital), reflecting genuine disagreement about the size of the opportunity.
- With the stock near $7.61, reaching $31 would require upside of roughly 307% — a very large move even for a clinical-stage biotech.
- Every one of the seven verified ratings is bullish (Buy or Outperform), with support tied largely to the Phase 3 relapsing MS readout expected by the end of 2026.
- The strongest supporting factor is positive Phase 2 data and a differentiated dual mechanism of action for vidofludimus calcium.
- The biggest risks are binary clinical-trial outcomes, ongoing cash burn, and shareholder dilution following the 1-for-10 reverse stock split completed in April 2026.
- For more on Immunic's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for additional context.
What the Analysts Are Saying
Seven current analyst targets were reviewed, all verifiable to a specific firm and date. The range is unusually wide — from Leerink Partners' $12.19 (Sept. 10, 2026) to LifeSci Capital's $56 (Sept. 11, 2026) — with H.C. Wainwright at $22, Stifel Nicolaus at $25, B. Riley Securities at $27, Roth MKM at $29, and Wedbush at $45 in between. The arithmetic mean is approximately $30.88, rounded to a clean $31 central target. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry.
Notably, the three highest targets imply a belief that vidofludimus calcium can secure regulatory approval and capture meaningful share in the relapsing MS market, while the lowest target reflects a more conservative, probability-weighted view of a single binary clinical outcome. Roth MKM analyst Boobalan Pachaiyappan raised his target to $29 from $19 in early September, citing the Phase 3 readout expected by year-end and arguing that positive data with a time-to-first-relapse hazard ratio near 0.73–0.81 would support approval.
Current Market Position and Path Toward the Target
IMUX shares closed near $7.61 in late October 2026. Reaching the $31 central target would require a move of about 307%, which is very large by any standard. The likely path would depend almost entirely on a successful Phase 3 readout for relapsing MS, followed by regulatory filing and the market's willingness to ascribe a substantially higher valuation to a pre-commercial asset. Without a positive data event, there is no fundamental earnings mechanism to close that gap in the near term.
What Could Support a Move Toward the Target
The central bull case rests on vidofludimus calcium's dual mechanism — first-in-class DHODH (dihydroorotate dehydrogenase) inhibition combined with Nurr1 activation — which analysts argue could offer an attractive efficacy and safety profile for oral MS therapy. Positive Phase 2 relapsing MS data underpin the Phase 3 program, and top-line results are expected before the end of 2026. A favorable readout could trigger a step-change revaluation, as the stock's sub-$10 price currently reflects a deeply discounted, risk-weighted view of success. Analyst commentary also notes that Novartis' Phase 3 success with remibrutinib validates the broader market for novel oral MS agents.
What Could Prevent the Target From Being Reached
The risks are substantial. Immunic is pre-revenue and generates operating losses — a GAAP net loss of about $34.1 million in its most recent reported quarter — and will likely require additional capital before commercialization. The April 2026 1-for-10 reverse stock split signaled balance-sheet stress and contributed to shareholder dilution, and D. Boral Capital downgraded the stock to Hold in April, arguing that deteriorating capital-structure dynamics outweighed near-term clinical upside. A failed or inconclusive Phase 3 trial, a delay, or a safety concern would likely reset the entire thesis. Competition in oral MS treatment is also intensifying.
Technical Levels and Market Structure
Technical analysis is complicated by the April 2026 reverse split, which distorts historical charts. On a split-adjusted basis, the stock set a post-split low near $5.24 in late December 2025 and traded into the mid-teens earlier in 2026 before pulling back toward current levels. The $10 mark is a natural psychological threshold, while the December low near $5.24 represents a notable support zone. No durable resistance has been meaningfully established above the recent trading range.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary, and for a binary event-driven biotech the practical timeline is compressed around data catalysts. Investors should monitor the Phase 3 relapsing MS readout expected by year-end 2026, quarterly cash burn and any financing or dilution announcements, upcoming earnings (scheduled around late October 2026), and analyst target revisions, which have already been volatile — several targets were cut sharply in 2026 following the reverse split.
Final Assessment
The $31 central target is the mean of seven verified analyst targets spanning $12.19 to $56 — a range that underscores how much legitimate disagreement surrounds Immunic's future. With the stock near $7.61, reaching that level requires a roughly 307% move, essentially contingent on a successful Phase 3 relapsing MS readout and a market reassessment of the company's oral-therapy franchise. The dual-mechanism science and unanimous bullish ratings support the bull case, while binary trial risk, cash burn, dilution, and rising competition form the principal obstacles. The near-term data readout and any financing decisions are the most important items to monitor, but no outcome — including reaching $31 — is guaranteed.
Using AI Tools for Biotech Research
In my own work following names like this, I rely on AI Daily Buy/Sell Signals to track shifting technical patterns and generate systematic buy or sell alerts across volatile clinical-stage stocks. The platform continuously scans thousands of securities using AI to highlight opportunities tied to catalysts like upcoming data readouts, helping me stay objective amid binary events. It is one of several tools I check regularly when evaluating event-driven names, and it has proven useful for monitoring IMUX alongside broader sector trends. This approach keeps analysis data-driven without replacing fundamental review of trial results or balance-sheet updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMUX's RSI Indicator ascending out of oversold territory
The RSI Indicator for IMUX moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 28 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 63 cases where IMUX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for IMUX just turned positive on October 15, 2026. Looking at past instances where IMUX's MACD turned positive, the stock continued to rise in 39 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Following a +7.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in 218 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
IMUX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for IMUX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for IMUX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.814) is normal, around the industry mean (3.037). P/E Ratio (-2.144) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. IMUX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases
Industry Biotechnology
Advertisement